Patents Examined by Retford Berko
  • Patent number: 7045141
    Abstract: The invention is directed toward an osteoimplant for application to a bone defect site to promote new bone growth at the site which comprises a new bone growth inducing composition of demineralized allograft bone material mixed with an aqueous phosphate buffered gelatin which when lyophilized to remove water from the composition cross links the gelatin to form a solid structure.
    Type: Grant
    Filed: May 20, 2002
    Date of Patent: May 16, 2006
    Assignee: Musculoskeletal Transplant Foundation
    Inventors: Barbara L. Merboth, Moon Hae Sunwoo, Arthur A. Gertzman
  • Patent number: 7018658
    Abstract: Tamsulosin pellets having an advantageous release profile are formed. The pellets have an enteric coating and release less than 10% of the tamsulosin in two hours in SGF.
    Type: Grant
    Filed: November 14, 2002
    Date of Patent: March 28, 2006
    Assignee: Synthon BV
    Inventor: Johannes J. Platteeuw
  • Patent number: 6987133
    Abstract: This invention relates to a topical spray preparation for burn treatment and microbial infections on human being or animals. This non-aerosol preparation contains an antimicrobial drug, i.e., silver sulfadiazine, as is dispersed or solubilized in a cream or lotion base matrix which can be sprayed directly from a common trigger spray device. The key component of the matrix can be characterized by it having a suitable molecular weight polymer of cross-linked acrylic acid, such as Carbomers or non-ionic surfactants such as polyoxyethylene alkyl ethers, or any combination of the above materials.
    Type: Grant
    Filed: April 1, 2003
    Date of Patent: January 17, 2006
    Assignee: Sage Pharmaceuticals, Inc.
    Inventor: Jivn-Ren Chen
  • Patent number: 6984392
    Abstract: The invention relates to an antimicrobial material for implanting in bones and for coating or producing an implant or an implantable medical device, whereby particles formed from an antimicrobial material are remotely dispersed inside a matrix material that forms a matrix when hardened. In order to improve the compatibility of the antimicrobial material, the invention provides that the metal is formed from aggregates of primary particles having an average particle size ranging from 10 to 100 nm.
    Type: Grant
    Filed: August 28, 2001
    Date of Patent: January 10, 2006
    Assignee: Bio-Gate Bioinnovative Materials GmbH
    Inventors: Thorsten Bechert, Peter Steinrücke
  • Patent number: 6949258
    Abstract: The invention is directed to an oral biological preparation for specific delivery in colon, especially an oral insulin preparation for specific delivery in colon.
    Type: Grant
    Filed: June 7, 2001
    Date of Patent: September 27, 2005
    Inventor: Junshou Zhang
  • Patent number: 6908609
    Abstract: The subject invention is a method and material for removing fluid from the intestinal tract of a host and may be useful in treating animals or human patients suffering from fluid overload states. In one embodiment, the subject method involves ingesting an enterically coated non-systemic, non-toxic, non-digestible, water absorbing polymer which absorbs fluid while passing through the intestinal tract. The polymer is excreted in the feces wherein the polymer and absorbed fluid is removed from the body. Preferred polymers include super absorbent acrylic acid polymers, preferably provided in bead form. The polymers may include functional groups for selectively removing blood borne waste products, e.g. urea, from the G.I. tract.
    Type: Grant
    Filed: November 6, 2001
    Date of Patent: June 21, 2005
    Assignee: Dow Global Technologies Inc.
    Inventors: Jaime Simon, Alan D. Strickland
  • Patent number: 6899893
    Abstract: This invention is to provide an agent for therapy and prevention of allergic diseases which has no adverse action, shows a high safety even by administration for a long period and is able to be utilized to food and/or beverage, cosmetics, etc. which are used daily. To be specific, it provides antiallergic agent and anti-inflammatory agent characterized in containing at least one polyphenol selected from strictinin and methylated derivatives thereof as an effective ingredient; a method for the addition of an antiallergic agent for oral administration or an anti-inflammatory agent for oral administration which is characterized in containing at least one polyphenol selected from strictinin and methylated derivatives thereof as an effective ingredient to food and/or beverage for prevention, suppression and mitigation of allergic symptoms or inflammatory symptoms.
    Type: Grant
    Filed: April 17, 2003
    Date of Patent: May 31, 2005
    Assignees: National Agriculture Research Organization, Bio-oriented Technology Research Advancement Institution
    Inventors: Kenkou Tsuji, Mari Yamamoto, Keiko Kawamoto, Hirofumi Tachibana
  • Patent number: 6896896
    Abstract: The present invention relates to functional foods or cosmetics containing sphingoglycolipids and a process of producing the same.
    Type: Grant
    Filed: July 17, 2001
    Date of Patent: May 24, 2005
    Assignee: Unitika Ltd.
    Inventors: Kenji Miyanishi, Takahiro Ono, Kazue Nawa, Mayumi Hayashi, Katsuyuki Mukai
  • Patent number: 6893661
    Abstract: An extended release dosage composition of pharmaceutically active substances that have a water contact angle (?) such that cos ? is between +0.9848 and ?0.9848 presented as a matrix tablet containing the said pharmaceutically active substances, with/without suitable pharmaceutical excipients in intimate mixture with two groups of intelligent polymers having opposing wettability characteristics, one demonstrating a stronger tendency towards hydrophobicity and the other a stronger tendency towards hydrophilicity, the polymer combination being between the ratios of 1:50 and 50:1 amounts effective to control the release of said pharmaceutically active substances in a mathematically predictable manner, wherein the polymer demonstrating a stronger tendency towards hydrophobicity is not less than 5% wt/wt and preferably between 5-70% wt/wt of the final formulation composition.
    Type: Grant
    Filed: April 3, 1998
    Date of Patent: May 17, 2005
    Assignee: Biovail Corporation
    Inventors: Isa Odidi, Amina Odidi
  • Patent number: 6893649
    Abstract: A solid powder cosmetic is provided which is superior in availability and formability. The solid powder cosmetic comprises 10 to 80 wt % of extender, 0.1 to 40 wt % of color pigment, and 0.5 to 80 wt % of spherical resin particles characterized by an average volume particle size of 2.0 to 20.0 ?m, a glass-transition temperature of 10 to 100° C. and a number average molecular weight of 5000 to 20000. Further, the solid powder cosmetic has an average volume particle size distribution GSDv of the spherical resin particles being 1.3 or less, and a shape factor SF1 of the spherical resin particles being 100 to 140.
    Type: Grant
    Filed: September 9, 2002
    Date of Patent: May 17, 2005
    Assignee: Fuji Xerox Co., Ltd.
    Inventors: Yuki Sasaki, Yasuo Matsumura
  • Patent number: 6887458
    Abstract: The present invention relates to a vascular embolic material for use in the treatment of an angiotropy of various tumors and a vascular malformation. Specifically, the present invention relates to a vascular embolic material having the specific morphological, physicochemical and radiological characteristics and multifunction in the form of a bead or a sponge comprising a mixture of a hydrophilic polymer material and a metal material. The specific physicochemical and radiological characteristics of the vascular embolic material according to the present invention facilitate its clinical use and aid in the diagnosis before and after the embolization. Further, a local radiation treatment and anticancer treatment is possible and thus the therapeutic effect on said disorders can be enhanced.
    Type: Grant
    Filed: May 3, 2000
    Date of Patent: May 3, 2005
    Inventors: Kyu-Ho Lee, Kyung-Chae Kim
  • Patent number: 6875445
    Abstract: A composition for inhibiting gastrointestinal absorption of phosphorous in an individual. The composition includes a quantity of calcium acetate sufficient to bind the phosphorous in the gastrointestinal tract of the individual. The calcium acetate has a bulk density of between 0.50 kg/L and 0.80 kg/L and is dimensioned to form a caplet for fitting within a capsule in a manner that optimizes the volume of the capsule. Also provided is a method for administering the calcium acetate composition of the present invention to an individual to reduce phosphorous absorption by binding with the phosphorous in their gastrointestinal tract.
    Type: Grant
    Filed: October 24, 2002
    Date of Patent: April 5, 2005
    Assignee: Nabi Biopharmaceuticals
    Inventors: Edmund V. Dennett, Jr., Robert M. Raleigh, Jr., Bruce H. Aronson
  • Patent number: 6861071
    Abstract: A solid preparation improved in oral absorption and reduced in fluctuations of oral absorption can be obtained by incorporating an organic acid, particularly tartaric acid, in a solid preparation having, as an active ingredient, a high content of a quinolone compound, particularly sitafloxacin, having poor water solubility at pH around neutrality.
    Type: Grant
    Filed: August 7, 2001
    Date of Patent: March 1, 2005
    Assignee: Daiichi Pharmaceutical Co., Ltd.
    Inventors: Katsuo Kataoka, Hiroshi Kikuchi, Tatsuya Suzuki, Takahiro Shimaya, Hideo Kobayashi, Akira Kurosawa, Koichi Ishido
  • Patent number: 6838092
    Abstract: The present invention relates to effervescent compositions containing active ingredients, in particular dry plant extracts, wherein the acid donor of the effervescent couple is constituted by a dried fruit juice with a natural acid pH, such as freeze-dried citrus fruit juice.
    Type: Grant
    Filed: March 31, 2003
    Date of Patent: January 4, 2005
    Assignee: Aboca S.p.A.
    Inventor: Valentino Mercati
  • Patent number: 6740337
    Abstract: The present invention relates to a bioavailable pharmaceutical composition of 13-cis vitamin A acid (also known as 13-cis retinoic acid and isotretinoin) and a process for preparing the same. 13-cis vitamin A acid is a relatively water insoluble compound that degrades when exposed to light and atmospheric oxygen. Due to its instability and relative insolubility, the bioavailability of the drug after oral administration is difficult to achieve and has always been a challenge to a development pharmacist. It would therefore be desirable to provide a dosage form in which the drug is stable and predictably bioavailable.
    Type: Grant
    Filed: April 9, 2001
    Date of Patent: May 25, 2004
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Abha Pant, Inderdeep Bhatia, Sunilendu Bhushan Roy, Rajiv Malik
  • Patent number: 6649145
    Abstract: Disclosed are methods and compositions for increasing tissue oxygen levels by administration of superoxygenated compositions of tissue surfaces. The methods are applicable to treatment of a wide variety of conditions including burns, bedsores, ulcers, necrosis and anaerobic infections.
    Type: Grant
    Filed: January 18, 2002
    Date of Patent: November 18, 2003
    Assignee: Hydron Technologies, Inc.
    Inventors: Terrence S. McGrath, Charles Fox
  • Patent number: RE39181
    Abstract: The present invention is concerned with physicochemically stable aqueous solutions of risperidone for oral and parenteral administration; processes for preparing such formulations.
    Type: Grant
    Filed: December 4, 2001
    Date of Patent: July 11, 2006
    Inventors: Marc Karel Jozef François, Willy Maria Albert Carlo Dries